The landmark India-UK Comprehensive Economic Trade Agreement (CETA) came into effect on July 15, 2026, marking a new chapter for Indian pharmaceutical exports to Britain. The Pharmaceutical Export Promotion Council of India (Pharmexcil) projects that Indian pharma exports to the UK will grow by 8.7%, reaching $981 million by the end of FY27.
📈 India-UK CETA: Key Pharma Export Numbers
The India-UK CETA, negotiated over several years, eliminates tariffs on 99% of Indian exports entering the United Kingdom. For the pharmaceutical sector, this duty-free access is expected to provide a significant competitive advantage over non-FTA countries.
- Projected pharma export growth: 8.7% to $981 million by FY27 — as reported by Pharmexcil (ET Government, July 16, 2026)
- First-day impact: India exported over $140 million worth of goods to the UK on the first day of CETA implementation alone (Business Upturn, July 15, 2026)
- Tariff elimination: 99% of Indian exports now enter the UK duty-free, including all pharmaceutical products (Moneycontrol, July 2026)
- Current baseline: Indian pharma exports to the UK stood at approximately $903 million in FY26 before the CETA boost
🔬 Regulatory Priorities for Pharma Under the FTA
Ahead of the July 15 rollout, the Indian pharmaceutical industry flagged several regulatory priorities that will determine how effectively the sector capitalises on the trade deal (The Economic Times, July 2026):
- Mutual recognition of inspections: Indian manufacturers seek UK MHRA recognition of CDSCO GMP inspections, reducing duplication of audits
- Data exclusivity provisions: Clarity on how the UK’s data exclusivity rules apply to Indian generic manufacturers post-Brexit
- Supply chain security: Streamlined customs procedures for API and finished formulation shipments
- Biosimilar market access: A clear regulatory pathway for Indian biosimilars entering the UK market through the Medicines and Healthcare products Regulatory Agency (MHRA)
🏭 State-Level Impact: Telangana Leads the Way
The southern state of Telangana, home to Hyderabad’s vibrant pharma and biotech cluster, is particularly well-positioned to benefit from the CETA. On the first day of implementation, export consignments were flagged off from Hyderabad, underscoring the region’s readiness to leverage tariff-free UK access (The Hindu, July 15, 2026).
Telangana accounts for approximately 35% of India’s total pharmaceutical output and hosts major facilities of companies including Dr. Reddy’s, Aurobindo Pharma, Hetero, and Natco Pharma — all of which are expected to increase UK-bound shipments under the favourable tariff regime.
🌍 Broader Context: India’s FTA-Driven Export Strategy
The India-UK CETA is part of a broader Indian trade strategy to secure preferential market access for its pharmaceutical sector, which is the world’s largest supplier of generic medicines by volume:
- April 2026: US granted tariff exemptions for generic medicines, strengthening Indian pharma’s position in its largest export market
- January 2026: India-EU trade deal negotiations advanced with pharma as a key pillar (India Briefing, January 2026)
- Pharmexcil’s strategic roadmap: The council is hosting a “Chintan Shivir” in Ahmedabad to define a long-term roadmap leveraging these FTAs
💡 What This Means for Indian Generic Medicine Buyers
For international buyers and distributors of Indian generic medicines, the CETA brings several practical benefits:
- Lower barriers: Indian manufacturers exporting to the UK gain cost advantages that could translate into more competitive pricing across their global supply chains
- Quality assurance: The MHRA-CDSCO regulatory alignment discussions could pave the way for mutual recognition of GMP certifications, making it easier for buyers to trust Indian manufacturing standards
- Diversification: Increased UK market engagement means Indian pharma companies are expanding production capacity and quality systems — benefiting all export markets
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.